Rapid Nutrition Bolsters Product Line with Azurene Immunity Booster Traveller and SystemLS™ Fluid-Free Body Balance Amidst Year-End Manufacturing Surge

London, United Kingdom – 5 December 2023 - Rapid Nutrition PLC (Euronext Growth: ALRPD): Rapid Nutrition PLC an evidenced-based nutritional supplement company, is excited to announce the completion of production for Azurene Immunity Booster Traveller  as announced last week and the commencement of production for SystemLS™ Fluid-Free Body Balance. Positioned within the  rapidly growing cold and flu and weight loss supplement categories, respectively, these innovative products are anticipated to capture market share, with potential significant contributions to the company's topline revenue in 2024 and beyond.

The cold and flu supplement market is projected to witness robust growth, with a global market size expected to reach USD 22.7 billion by 2028, according to a report by Grand View Research. Azurene Immunity Booster Traveller, designed to help support the immune system during the winter months, strategically aligns with this trend. Rapid Nutrition aims to tap into this expanding market by providing a solution that combines advanced nutritional science with on-the-go convenience.

Simultaneously, the weight loss supplements market is experiencing a surge, with a forecasted global market size of USD 38.3 billion by 2028 reported Grand View Research. SystemLS™ Fluid-Free Body Balance, categorised under weight loss supplements, addresses the evolving needs of consumers seeking effective weight management solutions. Crafted with the highest standards, the product aims not only to support weight loss but also to help reduce excess water retention and prevent cramping, aligning with the market's demand for comprehensive weight management solutions.

CEO of Rapid Nutrition PLC, Simon St Ledger, expressed confidence in the market potential of these products, stating, "We are committed to aligning our product strategy with evolving market dynamics. The weight loss supplements market, in particular, presents a substantial opportunity, and SystemLS™ Fluid-Free Body Balance is poised to meet the diverse needs of consumers seeking comprehensive weight management solutions. These strategic moves underscore our commitment to sustained growth and market leadership."

As Rapid Nutrition prepares for the market release of these products, customers are invited to explore these offerings through its official website. Further updates and announcements will be shared as the products become available in the market.

For more information about Rapid Nutrition PLC and its product offerings, including market insights, please visit www.rnplc.com.

About Rapid Nutrition

Rapid Nutrition is a leading health and wellness company committed to providing innovative solutions for a healthier world. With a focus on research-backed formulas, we empower individuals to optimize their well-being and face life's challenges with confidence.

Investor Relations Contact:







This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).

Subscribe for Updates